Ignite Creation Date:
2025-12-24 @ 11:50 PM
Ignite Modification Date:
2026-02-28 @ 9:03 PM
Study NCT ID:
NCT02336451
Status:
COMPLETED
Last Update Posted:
2020-04-21
First Post:
2015-01-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | ALK-positive Non-small Cell Lung Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | ALK-positive | View |
| None | NSCLC | View |
| None | non-small cell lung cancer | View |
| None | brain metastasis | View |
| None | metastatic to the brain and/or to leptomeninges | View |
| None | ceritinib | View |
| None | LDK378 | View |
| None | NSCLC metastatic to the brain | View |
| None | leptomeninges harboring a confirmed ALK rearrangement | View |